Neisserial OMV Vaccines
奈瑟氏菌 OMV 疫苗
基本信息
- 批准号:10588243
- 负责人:
- 金额:$ 20.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-26 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdjuvantAntibiotic ResistanceAntigensBiological AssayChlamydiaClinical TrialsDataData ProtectionDatabasesDoseDrug Metabolic DetoxicationEffectivenessEpidemiologyEpitopesGeneticGoalsGonorrheaHealthHumanImmune SeraImmune responseImmunizationImmunizeImmunosuppressionIndividualInfectionInflammationIon ChannelIronLaboratoriesLicensingLipid AMeasuresMembraneMembrane ProteinsMethodsModelingMucous MembraneMusNeisseria gonorrhoeaeNeisseria meningitidisPathogenesisPharmaceutical PreparationsPreclinical TestingProteinsPublic HealthPublishingQualifyingQuality ControlRecombinantsRegimenReproductive Tract InfectionsResearchResearch PersonnelRiskRisk ReductionRouteSafe SexSafetySerogroup B Neisseria meningitidisSex CounselingStandardizationSurfaceTestingUniversitiesVaccinationVaccine AdjuvantVaccinesVesicleVirus-like particleWorkburden of illnessco-infectiondesignefflux pumpepidemiologic datagonorrhea vaccinein vivomanufacturabilitymouse modelnanodisknext generationnoveloverexpressionpre-clinical assessmentreproductive tractresistant straintoolvaccine candidatevaccine developmentvaccine efficacyvaccine evaluationvaccine platformvaccine-induced immunity
项目摘要
ABSTRACT
The goal of Project 2: “Neisserial outer membrane vesicle vaccines” within the Gonorrhea
Vaccine Cooperative Research Center (GV CRC) is to develop candidate Neisseria gonorrhoeae
(Ng) and Neisseria meningitidis (Nm) OMV vaccines that protect against gonorrhea. The premise
of this application is that an effective gonorrhea vaccine can be developed using neisserial OMVs
containing defined surface exposed, protective antigens. This premise is supported by exciting
new epidemiological evidence that serogroup B Nm OMVs can reduce the risk of gonorrhea and
preliminary data from our laboratories that show two different Nm OMV-based vaccines
accelerate clearance of Ng from experimentally infected mice. The Specific Aims of the
application are to: 1) Further develop a novel Nm OMV vaccine that demonstrates in vivo efficacy
against Ng, 2) Develop Ng OMV vaccines with increased expression of promising vaccine targets,
and 3) Develop next-generation Ng and, or Nm OMV vaccines consisting of OMVs combined with
nanodisc-displayed protein vaccines or Ng epitope-targeted virus-like-particle vaccines being
developed by other GV CRC investigators. OMVs will undergo standardized quality control for
structural integrity and composition and a rigorous pre-clinical assessment using state-of-the art
assays for measuring host immune responses and in vivo efficacy in mouse models of Ng lower
and upper reproductive tract (LRT, URT) infection. The most promising vaccines, defined by the
capacity to induce systemic and mucosal humoral and cellular immune responses and protect
against murine genital tract infection, will be selected for advancement to further pre-clinical
testing and clinical trials. We will also test the effect of licensed adjuvants on alleviating Ng-
induced immunosuppression of Ng OMV vaccine efficacy and utilize the database of immune
responses and in vivo protection data obtained from all candidate vaccines to define mechanisms
of vaccine-induced immunity.
抽象的
项目2的目标:淋病“奈瑟菌外膜囊泡疫苗”
疫苗合作研究中心(GV CRC)将开发候选淋病奈瑟菌
(Ng) 和脑膜炎奈瑟菌 (Nm) OMV 疫苗可预防淋病。前提
该应用的重点是可以使用奈瑟氏菌 OMV 开发有效的淋病疫苗
含有确定的表面暴露的保护性抗原。这个前提得到了令人兴奋的支持
新的流行病学证据表明 B 群 Nm OMV 可以降低淋病风险
我们实验室的初步数据显示两种不同的基于 Nm OMV 的疫苗
加速 Ng 从实验感染小鼠中的清除。具体目标
申请的目的是: 1) 进一步开发一种新型 Nm OMV 疫苗,该疫苗具有体内功效
针对 Ng,2) 开发 Ng OMV 疫苗,增加有希望的疫苗靶标的表达,
3) 开发下一代 Ng 和/或 Nm OMV 疫苗,由 OMV 与
纳米盘展示蛋白疫苗或 Ng 表位靶向病毒样颗粒疫苗
由其他 GV CRC 研究人员开发。 OMV 将接受标准化质量控制
结构完整性和成分以及使用最先进技术进行严格的临床前评估
用于测量 Ng 降低小鼠模型的宿主免疫反应和体内功效的测定法
和上生殖道(LRT、URT)感染。最有前途的疫苗,由
诱导全身和粘膜体液和细胞免疫反应并保护的能力
对抗小鼠生殖道感染,将被选择进行进一步的临床前研究
测试和临床试验。我们还将测试许可佐剂对缓解 Ng- 的效果。
Ng OMV 疫苗功效诱导免疫抑制并利用免疫数据库
从所有候选疫苗获得的反应和体内保护数据来定义机制
疫苗诱导的免疫。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ann E. Jerse其他文献
Gonococcal PorB: a multifaceted modulator of host immune responses
淋球菌孔蛋白B:宿主免疫反应的多面调节因子
- DOI:
10.1016/j.tim.2023.10.002 - 发表时间:
2024-04-01 - 期刊:
- 影响因子:14.900
- 作者:
Rebekah A. Jones;Ann E. Jerse;Christoph M. Tang - 通讯作者:
Christoph M. Tang
emNeisseria gonorrhoeae/em Coinfection during emChlamydia muridarum/em Genital Latency Does Not Modulate Murine Vaginal Bacterial Shedding
淋病奈瑟菌/鼠衣原体生殖器潜伏期间的合并感染不会调节小鼠阴道细菌脱落
- DOI:
10.1128/spectrum.04500-22 - 发表时间:
2023-05-18 - 期刊:
- 影响因子:3.800
- 作者:
Delia Onorini;Cory Ann Leonard;Regenia Phillips Campbell;Barbara Prähauser;Theresa Pesch;Robert V. Schoborg;Ann E. Jerse;Bernadetta Tarigan;Nicole Borel - 通讯作者:
Nicole Borel
Ann E. Jerse的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ann E. Jerse', 18)}}的其他基金
The Gonorrhea Vaccine Cooperative Research Center
淋病疫苗合作研究中心
- 批准号:
10362587 - 财政年份:2019
- 资助金额:
$ 20.19万 - 项目类别:
The Gonorrhea Vaccine Cooperative Research Center
淋病疫苗合作研究中心
- 批准号:
10588233 - 财政年份:2019
- 资助金额:
$ 20.19万 - 项目类别:
Continuing Preclinical Development of PPCM Vaginal Contraceptive MPT to IND
PPCM 阴道避孕药 MPT 至 IND 的持续临床前开发
- 批准号:
9889971 - 财政年份:2017
- 资助金额:
$ 20.19万 - 项目类别:
The Atlantic Coast Sexually Transmitted Infection Cooperative Research Center (AC
大西洋海岸性传播感染合作研究中心(AC
- 批准号:
9316484 - 财政年份:2014
- 资助金额:
$ 20.19万 - 项目类别:
The Atlantic Coast Sexually Transmitted Infection Cooperative Research Center (AC
大西洋海岸性传播感染合作研究中心(AC
- 批准号:
8769562 - 财政年份:2014
- 资助金额:
$ 20.19万 - 项目类别:
2014 International Pathogenic Neisseria Conference
2014年国际致病性奈瑟菌会议
- 批准号:
8785926 - 财政年份:2014
- 资助金额:
$ 20.19万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:














{{item.name}}会员




